2018 Q1 Form 10-Q Financial Statement
#000114420418027157 Filed on May 10, 2018
Income Statement
| Concept | 2018 Q1 | 2017 Q1 | 2016 Q4 |
|---|---|---|---|
| Revenue | $5.903M | $2.778M | $14.41M |
| YoY Change | 112.49% | 320.91% | 4161.83% |
| Cost Of Revenue | $1.472M | $469.0K | $430.0K |
| YoY Change | 213.86% | ||
| Gross Profit | $4.431M | $2.309M | $12.19M |
| YoY Change | 91.9% | ||
| Gross Profit Margin | 75.06% | 83.12% | 84.62% |
| Selling, General & Admin | $16.31M | $10.25M | $8.590M |
| YoY Change | 59.11% | 29.28% | 19.14% |
| % of Gross Profit | 368.13% | 444.0% | 70.47% |
| Research & Development | $24.96M | $8.404M | $10.58M |
| YoY Change | 196.98% | 8.63% | 83.68% |
| % of Gross Profit | 563.26% | 363.97% | 86.79% |
| Depreciation & Amortization | $196.0K | $682.0K | $830.0K |
| YoY Change | -71.26% | 16950.0% | 8200.0% |
| % of Gross Profit | 4.42% | 29.54% | 6.81% |
| Operating Expenses | $40.08M | $62.26M | $31.42M |
| YoY Change | -35.63% | 295.27% | 142.44% |
| Operating Profit | -$34.17M | -$19.13M | -$32.22M |
| YoY Change | 78.68% | 22.82% | 148.51% |
| Interest Expense | $2.083M | $698.0K | -$2.000M |
| YoY Change | 198.42% | 12.58% | -18.37% |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$1.970M | $3.015M | |
| YoY Change | -165.34% | -294.27% | |
| Pretax Income | -$36.14M | -$14.56M | -$21.30M |
| YoY Change | 148.23% | -12.5% | 41.25% |
| Income Tax | $0.00 | ||
| % Of Pretax Income | |||
| Net Earnings | -$21.02M | -$11.98M | -$17.43M |
| YoY Change | 75.41% | -1.83% | 44.82% |
| Net Earnings / Revenue | -356.06% | -431.32% | -121.01% |
| Basic Earnings Per Share | -$0.49 | ||
| Diluted Earnings Per Share | -$0.49 | -$296.8K | -$433.7K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 42.52M | 50.32M shares | 48.88M shares |
| Diluted Shares Outstanding | 42.52M |
Balance Sheet
| Concept | 2018 Q1 | 2017 Q1 | 2016 Q4 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $165.3M | $135.2M | $90.70M |
| YoY Change | 22.26% | 66.09% | -7.64% |
| Cash & Equivalents | $120.9M | $150.9M | $105.2M |
| Short-Term Investments | $41.30M | $1.200M | $2.400M |
| Other Short-Term Assets | $15.30M | $9.500M | $10.10M |
| YoY Change | 61.05% | 493.75% | 531.25% |
| Inventory | $222.0K | $204.0K | $203.0K |
| Prepaid Expenses | |||
| Receivables | $8.314M | $1.400M | $1.830M |
| Other Receivables | $11.00M | $5.400M | $6.900M |
| Total Short-Term Assets | $200.2M | $151.8M | $109.6M |
| YoY Change | 31.86% | 80.07% | 9.7% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $2.119M | $7.400M | $7.376M |
| YoY Change | -71.36% | 184.62% | 2287.06% |
| Goodwill | $18.65M | $18.65M | $18.65M |
| YoY Change | 0.0% | ||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | $1.300M | $300.0K | $300.0K |
| YoY Change | 333.33% | 20.0% | 20.0% |
| Other Assets | $936.0K | $16.30M | $394.0K |
| YoY Change | -94.26% | 8.67% | 816.28% |
| Total Long-Term Assets | $64.92M | $60.10M | $61.10M |
| YoY Change | 8.02% | 191.75% | 227.19% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $200.2M | $151.8M | $109.6M |
| Total Long-Term Assets | $64.92M | $60.10M | $61.10M |
| Total Assets | $265.1M | $211.9M | $170.7M |
| YoY Change | 25.09% | 102.0% | 43.94% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $44.80M | $24.90M | $24.30M |
| YoY Change | 79.92% | 982.61% | 1200.86% |
| Accrued Expenses | $21.71M | $11.12M | $10.08M |
| YoY Change | 95.27% | 42.56% | 17.64% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $12.70M | $5.300M | $2.000M |
| YoY Change | 139.62% | ||
| Total Short-Term Liabilities | $79.30M | $52.80M | $56.57M |
| YoY Change | 50.19% | 388.89% | 434.69% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $73.40M | $27.80M | $26.20M |
| YoY Change | 164.03% | 33.65% | 12.93% |
| Other Long-Term Liabilities | $4.759M | $5.000M | $5.014M |
| YoY Change | -4.82% | 108.33% | 758.56% |
| Total Long-Term Liabilities | $4.759M | $32.80M | $5.014M |
| YoY Change | -85.49% | 41.38% | 758.56% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $79.30M | $52.80M | $56.57M |
| Total Long-Term Liabilities | $4.759M | $32.80M | $5.014M |
| Total Liabilities | $157.5M | $164.2M | $87.76M |
| YoY Change | -4.06% | 172.31% | 155.59% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$333.1M | -$245.3M | |
| YoY Change | 28.97% | ||
| Common Stock | $52.00K | $49.00K | |
| YoY Change | 4.26% | ||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $41.65M | $47.70M | $38.50M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $265.1M | $211.9M | $170.7M |
| YoY Change | 25.09% | 102.0% | 43.94% |
Cashflow Statement
| Concept | 2018 Q1 | 2017 Q1 | 2016 Q4 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$21.02M | -$11.98M | -$17.43M |
| YoY Change | 75.41% | -1.83% | 44.82% |
| Depreciation, Depletion And Amortization | $196.0K | $682.0K | $830.0K |
| YoY Change | -71.26% | 16950.0% | 8200.0% |
| Cash From Operating Activities | -$27.84M | -$11.48M | -$17.97M |
| YoY Change | 142.65% | -1.42% | -728.32% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $765.0K | $261.0K | -$610.0K |
| YoY Change | 193.1% | -88.62% | 221.05% |
| Acquisitions | $4.626M | ||
| YoY Change | |||
| Other Investing Activities | -$1.080M | -$680.0K | -$690.0K |
| YoY Change | 58.82% | 223.81% | -102.34% |
| Cash From Investing Activities | -$1.840M | -$942.0K | -$1.300M |
| YoY Change | 95.33% | -65.11% | -104.44% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 39.66M | $58.16M | 25.96M |
| YoY Change | -31.82% | -2493.42% | -35.84% |
| NET CHANGE | |||
| Cash From Operating Activities | -27.84M | -$11.48M | -17.97M |
| Cash From Investing Activities | -1.840M | -$942.0K | -1.300M |
| Cash From Financing Activities | 39.66M | $58.16M | 25.96M |
| Net Change In Cash | 9.971M | $45.74M | 6.690M |
| YoY Change | -78.2% | -372.77% | -90.79% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$27.84M | -$11.48M | -$17.97M |
| Capital Expenditures | $765.0K | $261.0K | -$610.0K |
| Free Cash Flow | -$28.61M | -$11.74M | -$17.36M |
| YoY Change | 143.77% | -15.77% | -669.18% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2017Q1 | fbio |
Change In Fair Value Of Short Term Investments
ChangeInFairValueOfShortTermInvestments
|
-668000 | USD |
| CY2018Q1 | us-gaap |
Assets
Assets
|
265075000 | USD |
| CY2017Q4 | us-gaap |
Assets
Assets
|
245950000 | USD |
| CY2018Q1 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
332000 | USD |
| CY2018Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
12278000 | USD |
| CY2017Q4 | us-gaap |
Goodwill
Goodwill
|
18645000 | USD |
| CY2018Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
52000 | USD |
| CY2017Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
51000 | USD |
| CY2018Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
374254000 | USD |
| CY2017Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
364148000 | USD |
| CY2018Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-333145000 | USD |
| CY2017Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-312127000 | USD |
| CY2018Q1 | us-gaap |
Minority Interest
MinorityInterest
|
65895000 | USD |
| CY2017Q4 | us-gaap |
Minority Interest
MinorityInterest
|
67929000 | USD |
| CY2018Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
107546000 | USD |
| CY2017Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
120502000 | USD |
| CY2017Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
245950000 | USD |
| CY2018Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
265075000 | USD |
| CY2018Q1 | us-gaap |
Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
|
489000 | USD |
| CY2017Q4 | us-gaap |
Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
|
500000 | USD |
| CY2018Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-35486000 | USD |
| CY2017Q1 | us-gaap |
Revenues
Revenues
|
44682000 | USD |
| CY2017Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
611000 | USD |
| CY2017Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
315000 | USD |
| CY2018Q1 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
936000 | USD |
| CY2017Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
67428000 | USD |
| CY2018Q1 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
4759000 | USD |
| CY2018Q1 | us-gaap |
Liabilities
Liabilities
|
157529000 | USD |
| CY2018Q1 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
78000 | USD |
| CY2017Q4 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
87000 | USD |
| CY2018Q1 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
8314000 | USD |
| CY2017Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
7758000 | USD |
| CY2018Q1 | us-gaap |
Deposits With Clearing Organizations And Others Securities
DepositsWithClearingOrganizationsAndOthersSecurities
|
1041000 | USD |
| CY2017Q4 | us-gaap |
Deposits With Clearing Organizations And Others Securities
DepositsWithClearingOrganizationsAndOthersSecurities
|
1041000 | USD |
| CY2018Q1 | us-gaap |
Receivables From Brokers Dealers And Clearing Organizations
ReceivablesFromBrokersDealersAndClearingOrganizations
|
8464000 | USD |
| CY2017Q4 | us-gaap |
Receivables From Brokers Dealers And Clearing Organizations
ReceivablesFromBrokersDealersAndClearingOrganizations
|
7395000 | USD |
| CY2018Q1 | us-gaap |
Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
|
1534000 | USD |
| CY2017Q4 | us-gaap |
Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
|
1616000 | USD |
| CY2018Q1 | us-gaap |
Investment Owned At Fair Value
InvestmentOwnedAtFairValue
|
4278000 | USD |
| CY2017Q4 | us-gaap |
Investment Owned At Fair Value
InvestmentOwnedAtFairValue
|
1985000 | USD |
| CY2018Q1 | us-gaap |
Inventory Net
InventoryNet
|
222000 | USD |
| CY2017Q4 | us-gaap |
Inventory Net
InventoryNet
|
171000 | USD |
| CY2018Q1 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
44725000 | USD |
| CY2017Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
36127000 | USD |
| CY2018Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
10713000 | USD |
| CY2017Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
10065000 | USD |
| CY2018Q1 | us-gaap |
Financial Instruments Sold Not Yet Purchased At Fair Value
FinancialInstrumentsSoldNotYetPurchasedAtFairValue
|
0 | USD |
| CY2017Q4 | us-gaap |
Financial Instruments Sold Not Yet Purchased At Fair Value
FinancialInstrumentsSoldNotYetPurchasedAtFairValue
|
151000 | USD |
| CY2018Q1 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
12651000 | USD |
| CY2017Q4 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
4700000 | USD |
| CY2018Q1 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
1952000 | USD |
| CY2017Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
181000 | USD |
| CY2018Q1 | us-gaap |
Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
|
0 | USD |
| CY2018Q1 | us-gaap |
Short Term Investments
ShortTermInvestments
|
37002000 | USD |
| CY2017Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
36002000 | USD |
| CY2018Q1 | fbio |
Due To Related Parties Interest Expenses Current
DueToRelatedPartiesInterestExpensesCurrent
|
657000 | USD |
| CY2017Q4 | fbio |
Due To Related Parties Interest Expenses Current
DueToRelatedPartiesInterestExpensesCurrent
|
669000 | USD |
| CY2018Q1 | us-gaap |
Due From Other Related Parties Current
DueFromOtherRelatedPartiesCurrent
|
944000 | USD |
| CY2017Q4 | us-gaap |
Due From Other Related Parties Current
DueFromOtherRelatedPartiesCurrent
|
618000 | USD |
| CY2018Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
14338000 | USD |
| CY2017Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
12680000 | USD |
| CY2018Q1 | us-gaap |
Assets Current
AssetsCurrent
|
200157000 | USD |
| CY2017Q4 | us-gaap |
Assets Current
AssetsCurrent
|
183181000 | USD |
| CY2018Q1 | fbio |
Warrants Issuable Current
WarrantsIssuableCurrent
|
6671000 | USD |
| CY2017Q4 | fbio |
Warrants Issuable Current
WarrantsIssuableCurrent
|
5597000 | USD |
| CY2017Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
9513000 | USD |
| CY2018Q1 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
17387000 | USD |
| CY2017Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
17387000 | USD |
| CY2018Q1 | us-gaap |
Long Term Investments
LongTermInvestments
|
1272000 | USD |
| CY2017Q4 | us-gaap |
Long Term Investments
LongTermInvestments
|
1390000 | USD |
| CY2018Q1 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
14400000 | USD |
| CY2017Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
15223000 | USD |
| CY2018Q1 | us-gaap |
Goodwill
Goodwill
|
18645000 | USD |
| CY2018Q1 | us-gaap |
Other Notes Payable Current
OtherNotesPayableCurrent
|
0 | USD |
| CY2018Q1 | us-gaap |
Long Term Notes Payable
LongTermNotesPayable
|
73444000 | USD |
| CY2017Q4 | us-gaap |
Long Term Notes Payable
LongTermNotesPayable
|
43222000 | USD |
| CY2017Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-14562000 | USD |
| CY2017Q1 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-2580000 | USD |
| CY2017Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-11982000 | USD |
| CY2017Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.3 | |
| CY2017Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
40357711 | shares |
| CY2017Q1 | fbio |
Interestexpenseandfinancefees
Interestexpenseandfinancefees
|
698000 | USD |
| CY2017Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-4342000 | USD |
| CY2017Q1 | fbio |
Changeinfairvalueofsubsidiaryconvertiblenote
Changeinfairvalueofsubsidiaryconvertiblenote
|
-97000 | USD |
| CY2018Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
284000 | USD |
| CY2018Q1 | fbio |
Change In Fair Value Of Short Term Investments
ChangeInFairValueOfShortTermInvestments
|
-118000 | USD |
| CY2018Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-38218000 | USD |
| CY2018Q1 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-17200000 | USD |
| CY2018Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-21018000 | USD |
| CY2018Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.49 | |
| CY2018Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
42518403 | shares |
| CY2018Q1 | fbio |
Interestexpenseandfinancefees
Interestexpenseandfinancefees
|
2083000 | USD |
| CY2018Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
1065000 | USD |
| CY2018Q1 | fbio |
Changeinfairvalueofsubsidiaryconvertiblenote
Changeinfairvalueofsubsidiaryconvertiblenote
|
250000 | USD |
| CY2018Q1 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
341000 | USD |
| CY2017Q1 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
246000 | USD |
| CY2018Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
5053000 | USD |
| CY2017Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2929000 | USD |
| CY2018Q1 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
19000 | USD |
| CY2017Q1 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
-4000 | USD |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-27575000 | USD |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-11475000 | USD |
| CY2018Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
801000 | USD |
| CY2017Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
261000 | USD |
| CY2018Q1 | us-gaap |
Proceeds From Other Deposits
ProceedsFromOtherDeposits
|
0 | USD |
| CY2017Q1 | us-gaap |
Proceeds From Other Deposits
ProceedsFromOtherDeposits
|
3000 | USD |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-1975000 | USD |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-942000 | USD |
| CY2018Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
1939000 | USD |
| CY2017Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-635000 | USD |
| CY2018Q1 | us-gaap |
Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
|
17000 | USD |
| CY2017Q1 | us-gaap |
Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
|
2000 | USD |
| CY2017Q1 | us-gaap |
Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
|
1265000 | USD |
| CY2018Q1 | fbio |
Payment For Research And Development Licenses
PaymentForResearchAndDevelopmentLicenses
|
75000 | USD |
| CY2017Q1 | fbio |
Payment For Research And Development Licenses
PaymentForResearchAndDevelopmentLicenses
|
665000 | USD |
| CY2018Q1 | us-gaap |
Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
|
97000 | USD |
| CY2018Q1 | us-gaap |
Cost Of Goods Sold Amortization
CostOfGoodsSoldAmortization
|
133000 | USD |
| CY2017Q1 | us-gaap |
Cost Of Goods Sold Amortization
CostOfGoodsSoldAmortization
|
133000 | USD |
| CY2018Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
556000 | USD |
| CY2017Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-462000 | USD |
| CY2018Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
51000 | USD |
| CY2017Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
1000 | USD |
| CY2018Q1 | us-gaap |
Increase Decrease Due From Other Related Parties
IncreaseDecreaseDueFromOtherRelatedParties
|
326000 | USD |
| CY2017Q1 | us-gaap |
Increase Decrease Due From Other Related Parties
IncreaseDecreaseDueFromOtherRelatedParties
|
-756000 | USD |
| CY2018Q1 | fbio |
Amortization Of Forgivable Loans To Registered Representatives
AmortizationOfForgivableLoansToRegisteredRepresentatives
|
160000 | USD |
| CY2017Q1 | fbio |
Amortization Of Forgivable Loans To Registered Representatives
AmortizationOfForgivableLoansToRegisteredRepresentatives
|
201000 | USD |
| CY2018Q1 | fbio |
Amortization Of Deferred Clearing Credit
AmortizationOfDeferredClearingCredit
|
-53000 | USD |
| CY2017Q1 | fbio |
Amortization Of Deferred Clearing Credit
AmortizationOfDeferredClearingCredit
|
-52000 | USD |
| CY2018Q1 | us-gaap |
Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
|
-20000 | USD |
| CY2017Q1 | us-gaap |
Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
|
115000 | USD |
| CY2018Q1 | fbio |
Change In Fair Value Of Contingently Issuable Warrants
ChangeInFairValueOfContingentlyIssuableWarrants
|
1065000 | USD |
| CY2017Q1 | fbio |
Change In Fair Value Of Contingently Issuable Warrants
ChangeInFairValueOfContingentlyIssuableWarrants
|
-4342000 | USD |
| CY2018Q1 | us-gaap |
Increase Decrease In Broker Dealer Related Receivables Payables Net
IncreaseDecreaseInBrokerDealerRelatedReceivablesPayablesNet
|
1069000 | USD |
| CY2017Q1 | us-gaap |
Increase Decrease In Broker Dealer Related Receivables Payables Net
IncreaseDecreaseInBrokerDealerRelatedReceivablesPayablesNet
|
-499000 | USD |
| CY2018Q1 | us-gaap |
Increase Decrease In Other Loans
IncreaseDecreaseInOtherLoans
|
78000 | USD |
| CY2017Q1 | us-gaap |
Increase Decrease In Other Loans
IncreaseDecreaseInOtherLoans
|
17000 | USD |
| CY2018Q1 | us-gaap |
Increase Decrease In Marketable Securities Restricted
IncreaseDecreaseInMarketableSecuritiesRestricted
|
2293000 | USD |
| CY2017Q1 | us-gaap |
Increase Decrease In Marketable Securities Restricted
IncreaseDecreaseInMarketableSecuritiesRestricted
|
-1151000 | USD |
| CY2018Q1 | us-gaap |
Increase Decrease In Financial Instruments Sold Not Yet Purchased
IncreaseDecreaseInFinancialInstrumentsSoldNotYetPurchased
|
-151000 | USD |
| CY2017Q1 | us-gaap |
Increase Decrease In Financial Instruments Sold Not Yet Purchased
IncreaseDecreaseInFinancialInstrumentsSoldNotYetPurchased
|
-297000 | USD |
| CY2018Q1 | us-gaap |
Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
|
-12000 | USD |
| CY2017Q1 | us-gaap |
Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
|
30000 | USD |
| CY2018Q1 | us-gaap |
Payments For Proceeds From Businesses And Interest In Affiliates
PaymentsForProceedsFromBusinessesAndInterestInAffiliates
|
124000 | USD |
| CY2017Q1 | us-gaap |
Payments For Proceeds From Businesses And Interest In Affiliates
PaymentsForProceedsFromBusinessesAndInterestInAffiliates
|
19000 | USD |
| CY2018Q1 | us-gaap |
Depreciation
Depreciation
|
365000 | USD |
| CY2017Q1 | us-gaap |
Depreciation
Depreciation
|
274000 | USD |
| CY2018Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
690000 | USD |
| CY2017Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
408000 | USD |
| CY2018Q1 | us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
25000000 | USD |
| CY2017Q1 | us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
0 | USD |
| CY2018Q1 | us-gaap |
Proceeds From Collection Of Notes Receivable
ProceedsFromCollectionOfNotesReceivable
|
25000 | USD |
| CY2017Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-1882000 | USD |
| CY2018Q1 | fbio |
Change In Fair Value Of Subsidiaries Assets And Liabilities
ChangeInFairValueOfSubsidiariesAssetsAndLiabilities
|
4000 | USD |
| CY2017Q1 | fbio |
Change In Fair Value Of Subsidiaries Assets And Liabilities
ChangeInFairValueOfSubsidiariesAssetsAndLiabilities
|
11000 | USD |
| CY2017Q1 | us-gaap |
Proceeds From Collection Of Notes Receivable
ProceedsFromCollectionOfNotesReceivable
|
0 | USD |
| CY2018Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
10105000 | USD |
| CY2017Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
45743000 | USD |
| CY2016Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
105184000 | USD |
| CY2017Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
150927000 | USD |
| CY2018Q1 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
1000 | USD |
| CY2017Q1 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
1000 | USD |
| CY2018Q1 | fbio |
Convertible Notes Conversion Converted Instrument Amount
ConvertibleNotesConversionConvertedInstrumentAmount
|
0 | USD |
| CY2017Q1 | fbio |
Convertible Notes Conversion Converted Instrument Amount
ConvertibleNotesConversionConvertedInstrumentAmount
|
158000 | USD |
| CY2018Q1 | fbio |
Issue Of Common Stock For Acquiring License Value
IssueOfCommonStockForAcquiringLicenseValue
|
0 | USD |
| CY2017Q1 | fbio |
Issue Of Common Stock For Acquiring License Value
IssueOfCommonStockForAcquiringLicenseValue
|
1682000 | USD |
| CY2018Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
2000 | USD |
| CY2017Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
4000 | USD |
| CY2018Q1 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
13650000 | USD |
| CY2018Q1 | us-gaap |
Investments In And Advances To Affiliates At Fair Value Period Increase Decrease
InvestmentsInAndAdvancesToAffiliatesAtFairValuePeriodIncreaseDecrease
|
100000 | USD |
| CY2018Q1 | us-gaap |
Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
|
1272000 | USD |
| CY2018Q1 | us-gaap |
Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
|
1272000 | USD |
| CY2018Q1 | us-gaap |
Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
|
12729000 | USD |
| CY2017Q4 | us-gaap |
Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
|
1390000 | USD |
| CY2017Q4 | us-gaap |
Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
|
1390000 | USD |
| CY2017Q4 | us-gaap |
Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
|
14846000 | USD |
| CY2017Q4 | us-gaap |
Long Term Debt
LongTermDebt
|
67544000 | USD |
| CY2017Q4 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
1035000 | USD |
| CY2018Q1 | us-gaap |
Interest Expense
InterestExpense
|
2083000 | USD |
| CY2017Q1 | us-gaap |
Interest Expense
InterestExpense
|
698000 | USD |
| CY2018Q1 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
6002000 | USD |
| CY2017Q4 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
5279000 | USD |
| CY2018Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
1497000 | USD |
| CY2017Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
1625000 | USD |
| CY2018Q1 | fbio |
Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
|
7061000 | USD |
| CY2017Q4 | fbio |
Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
|
4046000 | USD |
| CY2018Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
646000 | USD |
| CY2017Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
1030000 | USD |
| CY2018Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
21714000 | USD |
| CY2017Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
17632000 | USD |
| CY2018Q1 | fbio |
Accrued Expenses Releted To Dr Falk Pharma Milestone
AccruedExpensesReletedToDrFalkPharmaMilestone
|
3059000 | USD |
| CY2017Q4 | fbio |
Accrued Expenses Releted To Dr Falk Pharma Milestone
AccruedExpensesReletedToDrFalkPharmaMilestone
|
3059000 | USD |
| CY2018Q1 | fbio |
Deferred Rent And Long Term Lease Abandonment Non Current
DeferredRentAndLongTermLeaseAbandonmentNonCurrent
|
4759000 | USD |
| CY2017Q4 | fbio |
Deferred Rent And Long Term Lease Abandonment Non Current
DeferredRentAndLongTermLeaseAbandonmentNonCurrent
|
4739000 | USD |
| CY2018Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
17688788 | shares |
| CY2017Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
14510348 | shares |
| CY2018Q1 | us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
5053000 | USD |
| CY2017Q1 | us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
2929000 | USD |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
3.78 | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
1351080000 | USD |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
0 | USD |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
3.78 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
1701361000 | USD |
| CY2018Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
|
P3Y8M5D | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
|
3.75 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
|
1701361000 | USD |
| CY2018Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P3Y8M16D | |
| CY2018Q1 | fbio |
Sharebased Compensation Arrangement By Sharebased Payment Other Than Options Forfeited Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentOtherThanOptionsForfeitedWeightedAverageRemainingContractualTerm
|
P0Y | |
| CY2018Q1 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
1472000 | USD |
| CY2018Q1 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
2764000 | USD |
| CY2018Q1 | fbio |
Research And Development Expenses Including Intangible Assets
ResearchAndDevelopmentExpensesIncludingIntangibleAssets
|
25055000 | USD |
| CY2018Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
10784000 | USD |
| CY2017Q1 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
469000 | USD |
| CY2017Q1 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
2267000 | USD |
| CY2017Q1 | fbio |
Research And Development Expenses Including Intangible Assets
ResearchAndDevelopmentExpensesIncludingIntangibleAssets
|
8404000 | USD |
| CY2017Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
7985000 | USD |
| CY2018Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0px; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0px; font-size-adjust: none; font-stretch: normal" align="justify"><strong>Use of Estimates</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived and intangible assets, fair value measurements, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, derivative warrant liabilities, revenue with customers, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2017Q4 | us-gaap |
Due To Related Parties Current
DueToRelatedPartiesCurrent
|
222000 | USD |
| CY2018Q1 | us-gaap |
Due To Related Parties Current
DueToRelatedPartiesCurrent
|
124000 | USD |
| CY2018Q1 | us-gaap |
Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
|
0 | USD |
| CY2017Q4 | us-gaap |
Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
|
973000 | USD |
| CY2018Q1 | us-gaap |
Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
|
1047000 | USD |
| CY2017Q4 | us-gaap |
Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
|
62000 | USD |
| CY2017Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2018Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
15000000 | shares |
| CY2018Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
15000000 | shares |
| CY2017Q4 | fbio |
Preferred Stock Shares Designated
PreferredStockSharesDesignated
|
5000000 | shares |
| CY2018Q1 | fbio |
Preferred Stock Shares Designated
PreferredStockSharesDesignated
|
5000000 | shares |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
1000000 | shares |
| CY2018Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
1000000 | shares |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
1000000 | shares |
| CY2018Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
1000000 | shares |
| CY2017Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2018Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2018Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2017Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
50991285 | shares |
| CY2018Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
52686537 | shares |
| CY2017Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
50991285 | shares |
| CY2018Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
52686537 | shares |
| CY2018Q1 | us-gaap |
Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
|
104958 | shares |
| CY2017Q4 | us-gaap |
Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
|
158015 | shares |
| CY2017Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
14340000 | USD |
| CY2017Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
3015000 | USD |
| CY2018Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-2732000 | USD |
| CY2006Q4 | us-gaap |
Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
|
200000 | USD |
| CY2018Q1 | fbio |
Adjustments To Additional Paid In Capital Stock Issued For License Expenses
AdjustmentsToAdditionalPaidInCapitalStockIssuedForLicenseExpenses
|
22000 | USD |
| CY2018Q1 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
|
5053000 | USD |
| CY2018Q1 | fbio |
Adjustments To Additional Paid In Capital Subsidiary Public Offering
AdjustmentsToAdditionalPaidInCapitalSubsidiaryPublicOffering
|
20844000 | USD |
| CY2018Q1 | fbio |
Issuance Of Common Stock For At Market Offering
IssuanceOfCommonStockForAtMarketOffering
|
318000 | USD |
| CY2018Q1 | fbio |
Stock Issued During Period Value Cash Less Exercise Of Warrants
StockIssuedDuringPeriodValueCashLessExerciseOfWarrants
|
96000 | USD |
| CY2018Q1 | fbio |
Adjustments To Additional Paid In Capital At Market Offering Costs
AdjustmentsToAdditionalPaidInCapitalAtMarketOfferingCosts
|
-6000 | USD |
| CY2017Q1 | fbio |
Issuance Of Common Stock For License Expenses
IssuanceOfCommonStockForLicenseExpenses
|
-30000 | USD |
| CY2018Q1 | fbio |
Issuance Of Common Stock For License Expenses
IssuanceOfCommonStockForLicenseExpenses
|
0 | USD |
| CY2018Q1 | us-gaap |
Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
|
24000000 | USD |
| CY2017Q1 | us-gaap |
Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
|
0 | USD |
| CY2017Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
2917000 | USD |
| CY2017Q3 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
2872000 | USD |
| CY2017Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
644000 | USD |
| CY2017Q3 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
475000 | USD |
| CY2017Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2397000 | USD |
| CY2018Q1 | fbio |
Annual Management Services Agreement Fee Incomeexpense
AnnualManagementServicesAgreementFeeIncomeexpense
|
0 | USD |
| CY2018Q1 | us-gaap |
Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
|
83095000 | USD |
| CY2017 | us-gaap |
Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
|
100889000 | USD |
| CY2017 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-32960000 | USD |
| CY2018Q1 | fbio |
Accrued Expenses Related Party
AccruedExpensesRelatedParty
|
107000 | USD |
| CY2017Q4 | fbio |
Accrued Expenses Related Party
AccruedExpensesRelatedParty
|
95000 | USD |
| CY2018Q1 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
1091000 | USD |
| CY2017Q4 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
1411000 | USD |
| CY2018Q1 | fbio |
Accrued Coupon Expense Current
AccruedCouponExpenseCurrent
|
735000 | USD |
| CY2017Q4 | fbio |
Accrued Coupon Expense Current
AccruedCouponExpenseCurrent
|
0 | USD |
| CY2017Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
|
21833000 | USD |
| CY2018Q1 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
|
118000 | USD |
| CY2018Q1 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
|
-250000 | USD |
| CY2018Q1 | fbio |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Derivative Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisDerivativeLiabilityGainLossIncludedInEarnings
|
-1065000 | USD |
| CY2018Q1 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
|
20672000 | USD |
| CY2018Q1 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
|
-1858000 | USD |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2018Q1 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
|
0 | USD |
| CY2018Q1 | fbio |
Adjustments To Additional Paid In Capital Acquisition Of Business
AdjustmentsToAdditionalPaidInCapitalAcquisitionOfBusiness
|
-529000 | USD |
| CY2018Q1 | us-gaap |
Dividends Preferred Stock
DividendsPreferredStock
|
586000 | USD |
| CY2017 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P3Y11M12D | |
| CY2018Q1 | fbio |
Stock Issued During Period Value Interest Expense
StockIssuedDuringPeriodValueInterestExpense
|
-439000 | USD |
| CY2018Q1 | us-gaap |
Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
|
1298000 | USD |
| CY2017Q1 | us-gaap |
Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
|
0 | USD |
| CY2018Q1 | fbio |
Employee Stock Purchase Plan Compensation Expense Recognized
EmployeeStockPurchasePlanCompensationExpenseRecognized
|
38000 | USD |
| CY2017Q1 | fbio |
Employee Stock Purchase Plan Compensation Expense Recognized
EmployeeStockPurchasePlanCompensationExpenseRecognized
|
35000 | USD |
| CY2018Q1 | us-gaap |
Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
|
124000 | USD |
| CY2017Q1 | us-gaap |
Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
|
19000 | USD |
| CY2018Q1 | fbio |
Property Plant And Equipment Included In Account Payable And Accrued Liabilities
PropertyPlantAndEquipmentIncludedInAccountPayableAndAccruedLiabilities
|
2321000 | USD |
| CY2017Q1 | fbio |
Property Plant And Equipment Included In Account Payable And Accrued Liabilities
PropertyPlantAndEquipmentIncludedInAccountPayableAndAccruedLiabilities
|
0 | USD |
| CY2018Q1 | us-gaap |
Sales Revenue Goods Net
SalesRevenueGoodsNet
|
5509000 | USD |
| CY2018Q1 | us-gaap |
Brokerage Commissions Revenue
BrokerageCommissionsRevenue
|
25618000 | USD |
| CY2018Q1 | us-gaap |
Underwriting Income Loss
UnderwritingIncomeLoss
|
2700000 | USD |
| CY2018Q1 | fbio |
Private Placement Revenue
PrivatePlacementRevenue
|
9815000 | USD |
| CY2018Q1 | us-gaap |
Investment Advisory Fees
InvestmentAdvisoryFees
|
1314000 | USD |
| CY2018Q1 | us-gaap |
Revenue Other Financial Services
RevenueOtherFinancialServices
|
160000 | USD |
| CY2018Q1 | fbio |
Revenue From Contracts With Customers Excluding Other Revenue
RevenueFromContractsWithCustomersExcludingOtherRevenue
|
39607000 | USD |
| CY2018Q1 | us-gaap |
Other Sales Revenue Net
OtherSalesRevenueNet
|
9915000 | USD |
| CY2018Q1 | fbio |
Revenue From Contracts With Customers Including Other Revenue
RevenueFromContractsWithCustomersIncludingOtherRevenue
|
49522000 | USD |
| CY2018Q1 | us-gaap |
Noninterest Expense Transfer Agent And Custodian Fees
NoninterestExpenseTransferAgentAndCustodianFees
|
1700000 | USD |
| CY2018Q1 | fbio |
Description Of Fee Paid
DescriptionOfFeePaid
|
NSC received a fee of approximately $1.8 million, or 8% on the gross proceeds raised of $23.0 million. The fees were eliminated in consolidation. | |
| CY2018Q1 | fbio |
Revenue Recognition Milestone Method Payments Due
RevenueRecognitionMilestoneMethodPaymentsDue
|
500000 | USD |
| CY2018Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
1000 | USD |
| CY2017Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
1000 | USD |
| CY2018Q1 | us-gaap |
License And Services Revenue
LicenseAndServicesRevenue
|
400000 | USD |
| CY2018Q1 | us-gaap |
Paid In Kind Interest
PaidInKindInterest
|
489000 | USD |
| CY2017Q1 | us-gaap |
Paid In Kind Interest
PaidInKindInterest
|
0 | USD |
| CY2018Q1 | us-gaap |
Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
|
-98000 | USD |
| CY2017Q1 | us-gaap |
Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
|
0 | USD |
| CY2017Q4 | us-gaap |
Loss Contingency Accrual Carrying Value Current
LossContingencyAccrualCarryingValueCurrent
|
1800000 | USD |
| CY2017Q3 | us-gaap |
Loss Contingency Accrual Carrying Value Current
LossContingencyAccrualCarryingValueCurrent
|
2400000 | USD |
| CY2017Q4 | us-gaap |
Loss Contingency Accrual Provision
LossContingencyAccrualProvision
|
200000 | USD |
| CY2016Q4 | us-gaap |
Loss Contingency Accrual Provision
LossContingencyAccrualProvision
|
6000 | USD |
| CY2018Q1 | us-gaap |
Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
|
586000 | USD |
| CY2017Q1 | us-gaap |
Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
|
0 | USD |
| CY2018Q1 | fbio |
Proceeds From Issuance Of At Market Offering
ProceedsFromIssuanceOfAtMarketOffering
|
229000 | USD |
| CY2017Q1 | fbio |
Proceeds From Issuance Of At Market Offering
ProceedsFromIssuanceOfAtMarketOffering
|
0 | USD |
| CY2018Q1 | fbio |
Payment Of Cost Related To Atthemarket Offering
PaymentOfCostRelatedToAtthemarketOffering
|
6000 | USD |
| CY2017Q1 | fbio |
Payment Of Cost Related To Atthemarket Offering
PaymentOfCostRelatedToAtthemarketOffering
|
0 | USD |
| CY2017Q4 | us-gaap |
Legal Fees
LegalFees
|
400000 | USD |
| CY2016Q4 | us-gaap |
Legal Fees
LegalFees
|
500000 | USD |
| CY2018Q1 | us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
23011000 | USD |
| CY2017Q1 | us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
55904000 | USD |
| CY2018Q1 | us-gaap |
Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
|
2167000 | USD |
| CY2017Q1 | us-gaap |
Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
|
2998000 | USD |
| CY2018Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
96000 | USD |
| CY2017Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
0 | USD |
| CY2018Q1 | us-gaap |
Proceeds From Unsecured Notes Payable
ProceedsFromUnsecuredNotesPayable
|
0 | USD |
| CY2017Q1 | us-gaap |
Proceeds From Unsecured Notes Payable
ProceedsFromUnsecuredNotesPayable
|
3254000 | USD |
| CY2018Q1 | us-gaap |
Proceeds From Unsecured Lines Of Credit
ProceedsFromUnsecuredLinesOfCredit
|
0 | USD |
| CY2017Q1 | us-gaap |
Proceeds From Unsecured Lines Of Credit
ProceedsFromUnsecuredLinesOfCredit
|
2000000 | USD |
| CY2018Q1 | us-gaap |
Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
|
1858000 | USD |
| CY2017Q1 | us-gaap |
Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
|
0 | USD |
| CY2018Q1 | us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
255000 | USD |
| CY2017Q1 | us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
0 | USD |
| CY2018Q1 | us-gaap |
Proceeds From Other Debt
ProceedsFromOtherDebt
|
21707000 | USD |
| CY2018Q1 | us-gaap |
Repayments Of Other Debt
RepaymentsOfOtherDebt
|
1814000 | USD |
| CY2017Q1 | us-gaap |
Repayments Of Other Debt
RepaymentsOfOtherDebt
|
0 | USD |
| CY2017Q1 | us-gaap |
Proceeds From Other Debt
ProceedsFromOtherDebt
|
0 | USD |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
39655000 | USD |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
58160000 | USD |
| CY2018Q1 | us-gaap |
Research And Development In Process
ResearchAndDevelopmentInProcess
|
97000 | USD |
| CY2017Q1 | us-gaap |
Research And Development In Process
ResearchAndDevelopmentInProcess
|
1294000 | USD |
| CY2015Q1 | us-gaap |
Payments For Fees
PaymentsForFees
|
1000000 | USD |
| CY2018Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
41651000 | USD |
| CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
52573000 | USD |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1110501 | shares |
| CY2018Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
0 | shares |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1110501 | shares |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
1085501 | shares |
| CY2018Q1 | fbio |
Common Shares Issuable For Subordinated Note Interest Payable
CommonSharesIssuableForSubordinatedNoteInterestPayable
|
489000 | USD |
| CY2018Q1 | fbio |
Common Shares Issued For Subordinated Note Interest Expense
CommonSharesIssuedForSubordinatedNoteInterestExpense
|
0 | USD |
| CY2018Q1 | fbio |
Issuance Of Warrants In Conjunction With Subordinated Note Financing
IssuanceOfWarrantsInConjunctionWithSubordinatedNoteFinancing
|
0 | USD |
| CY2017Q1 | fbio |
Issuance Of Warrants In Conjunction With Subordinated Note Financing
IssuanceOfWarrantsInConjunctionWithSubordinatedNoteFinancing
|
206000 | USD |
| CY2018Q1 | fbio |
Receivable From Atm Issuances
ReceivableFromAtmIssuances
|
89000 | USD |
| CY2017Q1 | fbio |
Receivable From Atm Issuances
ReceivableFromAtmIssuances
|
0 | USD |
| CY2018Q1 | fbio |
Noncash Supplemental Information Common Shares Issued For Subordinated Note Financing Interest Expense
NoncashSupplementalInformationCommonSharesIssuedForSubordinatedNoteFinancingInterestExpense
|
500000 | USD |
| CY2017Q1 | fbio |
Noncash Supplemental Information Common Shares Issued For Subordinated Note Financing Interest Expense
NoncashSupplementalInformationCommonSharesIssuedForSubordinatedNoteFinancingInterestExpense
|
0 | USD |
| CY2018Q1 | us-gaap |
Long Term Debt
LongTermDebt
|
87142000 | USD |
| CY2018Q1 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
1047000 | USD |
| CY2017Q4 | us-gaap |
Notes Payable
NotesPayable
|
66509000 | USD |
| CY2018Q1 | us-gaap |
Notes Payable
NotesPayable
|
86095000 | USD |
| CY2018Q1 | fbio |
Lease Sharing Agreements Contributions To Property Under Lease
LeaseSharingAgreementsContributionsToPropertyUnderLease
|
32000 | USD |
| CY2018Q1 | fbio |
Collaborative Arrangement Fixed Fee
CollaborativeArrangementFixedFee
|
500000 | USD |
| CY2018Q1 | fbio |
Adjustments To Additional Paid In Capital And Noncontrolling Interest From Subsidiary Equity Issuance
AdjustmentsToAdditionalPaidInCapitalAndNoncontrollingInterestFromSubsidiaryEquityIssuance
|
0 | USD |
| CY2018Q1 | us-gaap |
Deferred Revenue
DeferredRevenue
|
690000 | USD |
| CY2017Q4 | us-gaap |
Deferred Revenue
DeferredRevenue
|
0 | USD |
| CY2017Q1 | us-gaap |
Other Underwriting Expense
OtherUnderwritingExpense
|
0 | USD |
| CY2018Q1 | us-gaap |
Other Underwriting Expense
OtherUnderwritingExpense
|
145000 | USD |
| CY2017Q1 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
0 | USD |
| CY2018Q1 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
690000 | USD |
| CY2018Q1 | fbio |
National Investment Banking Expenses
NationalInvestmentBankingExpenses
|
100000 | USD |
| CY2018Q1 | fbio |
Deferred Coupon Funding
DeferredCouponFunding
|
1516000 | USD |
| CY2017Q4 | fbio |
Deferred Coupon Funding
DeferredCouponFunding
|
1087000 | USD |
| CY2016Q3 | us-gaap |
Business Combination Contingent Consideration Arrangements Description
BusinessCombinationContingentConsiderationArrangementsDescription
|
Fortress contends that no such payment is due because a condition of the EUR 2.5 million payment was the delivery of a Clinical Study Report that addressed the primary and secondary objectives of a Phase II trial, and Fortress contends that Dr. Falk Pharma failed to deliver such a Clinical Study Report. Dr. Falk Pharma disputes that it failed to deliver such a report and further disputes that the delivery of such a report is a condition of Fortress’s obligation to make the EUR 2.5 million payment. After the parties’ attempts to negotiate a settlement of the dispute were unsuccessful, Dr. Falk Pharma filed a lawsuit against Fortress in the above-referenced Court in Frankfurt, Germany to recover the EUR 2.5 million plus interest and attorneys’ fees, and Fortress was served with the English translation of the lawsuit on August 11, 2016. Fortress retained local counsel and, on December 14, 2016, filed an answer to the complaint, denying that it had any liability to Dr. Falk Pharma. | |
| CY2018Q1 | fbio |
Return Reserve
ReturnReserve
|
700000 | USD |
| CY2017Q1 | fbio |
Return Reserve
ReturnReserve
|
100000 | USD |
| CY2018Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
12000 | USD |
| CY2018Q1 | us-gaap |
Revenues
Revenues
|
55425000 | USD |
| CY2018Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
90911000 | USD |
